Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?

Links:

How a Canadian scientist and a venomous lizard helped pave the way for Ozempic
The Discovery and Development of Liraglutide and Semaglutide
Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor
Insurers clamping down on doctors who prescribe Ozempic for weight loss
Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most
Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
Safety of Semaglutide
Semaglutide for the treatment of overweight and obesity: A review
Once-Weekly Semaglutide in Adolescents with Obesity
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data

Thanks to Doctor Dreamchip for our lovely theme song!

Support the show

Tesla’s energy storage business is growing faster than any other part of the company; plus, Apple bought Israeli startup Q.AI

TechCrunch Industry News

Apple earnings context and iPhone outlook

The AI-powered Podcast Player